Alesta Therapeutics is focused on developing innovative oral small molecule therapies aimed at treating rare diseases. The company is based in Leiden, Netherlands, and is advancing its clinical candidates through rigorous pre-GLP toxicology studies, with plans to initiate GLP toxicology studies soon. Their lead candidate, ALE1, is designed to treat hypophosphatasia (HPP), a rare genetic disorder that affects bone and teeth mineralization. Unlike current treatments that primarily address bone-related symptoms, ALE1 aims to provide a comprehensive solution for the full spectrum of HPP symptoms, with clinical studies expected to commence in 2025.

In addition to ALE1, Alesta is also developing ALE2, which targets Charcot-Marie-Tooth disease (CMT), a hereditary neurological disorder that impacts motor and sensory functions. ALE2 functions by inhibiting GCN2, a critical regulator of the Integrated Stress Response, which is activated by mutations in tRNA synthetases linked to CMT. This approach aims to mitigate chronic neurotoxicity associated with the disease, offering hope for improved treatment options for the approximately 126,000 affected individuals in the US and millions worldwide.

Netherlands

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

Alesta Therapeutics

Company Details